Pangaea Oncology, S.A. (BME:PANG)
Spain · Delayed Price · Currency is EUR 1.430
0.00 (0.00%)
Oct 6, 2026, 4:00 PM CET
Pangaea Oncology Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14.52 | 14.27 | 8 | 4.37 | 4.6 | |
Revenue Growth | 1.78% | 78.41% | 83.12% | -5.11% | 12.29% |
Cost of Revenue | 2.58 | 2.74 | 2.4 | 2.73 | 1.65 |
Gross Profit | 11.94 | 11.53 | 5.6 | 1.63 | 2.95 |
Selling, General & Admin | 15.25 | 14.04 | 9.35 | 5.35 | 4.41 |
Other Operating Expenses | -2.2 | -2.88 | -2.12 | -2.26 | -1.81 |
Operating Expenses | 15.83 | 13.72 | 9.05 | 4.33 | 3.59 |
Operating Income | -3.89 | -2.19 | -3.44 | -2.7 | -0.64 |
Interest Expense | -0.3 | -0.3 | -0.13 | -0.19 | -0.25 |
Interest & Investment Income | 0 | 0.02 | 0.12 | 0.02 | 0 |
Earnings From Equity Investments | - | - | -0.06 | -0.16 | -0.19 |
Currency Exchange Gain (Loss) | 0.01 | -0.01 | -0.01 | 0 | -0.01 |
Other Non Operating Income (Expenses) | 0.15 | 0.43 | 0.13 | 0.14 | 0.09 |
EBT Excluding Unusual Items | -4.02 | -2.06 | -3.39 | -2.88 | -1.01 |
Impairment of Goodwill | - | - | -0.51 | - | - |
Gain (Loss) on Sale of Investments | - | - | 0.39 | 0.04 | -0.09 |
Asset Writedown | - | 0.36 | - | - | - |
Pretax Income | -4.02 | -1.69 | -3.51 | -2.84 | -1.1 |
Income Tax Expense | -0.46 | -0.5 | 1.29 | -0.11 | -0.46 |
Earnings From Continuing Operations | -3.57 | -1.2 | -4.79 | -2.72 | -0.64 |
Earnings From Discontinued Operations | - | -0.07 | - | - | - |
Net Income to Company | -3.57 | -1.27 | -4.79 | -2.72 | -0.64 |
Minority Interest in Earnings | -0.03 | 0.1 | 0.14 | 0.01 | - |
Net Income | -3.6 | -1.17 | -4.66 | -2.71 | -0.64 |
Net Income to Common | -3.6 | -1.17 | -4.66 | -2.71 | -0.64 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 36 | - | 30 | 30 | 23 |
Shares Outstanding (Diluted) | 36 | - | 30 | 30 | 23 |
Shares Change | - | - | -0.98% | 35.11% | 20.34% |
EPS (Basic) | -0.10 | - | -0.15 | -0.09 | -0.03 |
EPS (Diluted) | -0.10 | - | -0.15 | -0.09 | -0.03 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.97 | -5.05 | -2.65 | -3.7 | -2.53 |
Free Cash Flow Per Share | -0.08 | - | -0.09 | -0.12 | -0.11 |
Gross Margin | 82.21% | 80.81% | 70.03% | 37.43% | 64.09% |
Operating Margin | -26.79% | -15.33% | -43.05% | -61.74% | -13.93% |
Profit Margin | -24.76% | -8.18% | -58.22% | -62.09% | -13.94% |
Free Cash Flow Margin | -20.44% | -35.38% | -33.18% | -84.61% | -54.89% |
EBITDA | -2.6 | -0.85 | -2.69 | -2.31 | -0.27 |
EBITDA Margin | -17.92% | -5.92% | -33.69% | -52.91% | -5.85% |
D&A For EBITDA | 1.29 | 1.34 | 0.75 | 0.39 | 0.37 |
EBIT | -3.89 | -2.19 | -3.44 | -2.7 | -0.64 |
EBIT Margin | -26.79% | -15.33% | -43.05% | -61.74% | -13.93% |
Revenue as Reported | - | - | 8 | 4.37 | - |
Advertising Expenses | 0.11 | 0.1 | 0.18 | 0.07 | 0.03 |